Hologic’s (HOLX) “Outperform” Rating Reiterated at Leerink Swann
HOLX has been the topic of a number of other research reports. Barclays PLC reiterated a hold rating and issued a $42.00 price objective on shares of Hologic in a report on Sunday, July 10th. Zacks Investment Research upgraded Hologic from a hold rating to a buy rating and set a $43.00 price target on the stock in a research note on Wednesday, September 28th. Bank of America Corp. restated a buy rating on shares of Hologic in a research note on Wednesday, June 22nd. Jefferies Group restated a buy rating and set a $42.00 price target on shares of Hologic in a research note on Tuesday, June 21st. Finally, Royal Bank Of Canada raised their price target on Hologic from $37.00 to $39.00 and gave the stock a sector perform rating in a research note on Monday, August 1st. Six equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $42.71.
Hologic (NASDAQ:HOLX) opened at 39.53 on Monday. Hologic has a 52 week low of $31.84 and a 52 week high of $41.66. The stock has a market cap of $10.97 billion, a price-to-earnings ratio of 43.58 and a beta of 1.00. The stock’s 50 day moving average price is $38.36 and its 200 day moving average price is $36.15.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, July 27th. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.03. The company had revenue of $717.40 million for the quarter, compared to analyst estimates of $703.66 million. Hologic had a return on equity of 26.25% and a net margin of 9.39%. Hologic’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.43 EPS. On average, analysts forecast that Hologic will post $1.94 earnings per share for the current year.
In other Hologic news, Director Nancy Leaming sold 8,179 shares of the firm’s stock in a transaction on Thursday, July 21st. The stock was sold at an average price of $37.00, for a total transaction of $302,623.00. Following the completion of the transaction, the director now owns 67,140 shares of the company’s stock, valued at $2,484,180. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.84% of the company’s stock.
Several large investors have recently made changes to their positions in HOLX. State Street Corp increased its stake in shares of Hologic by 26.4% in the first quarter. State Street Corp now owns 10,295,836 shares of the company’s stock worth $355,210,000 after buying an additional 2,150,544 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Hologic by 8.1% in the second quarter. Vanguard Group Inc. now owns 26,537,173 shares of the company’s stock worth $918,185,000 after buying an additional 1,992,898 shares in the last quarter. Wedge Capital Management L L P NC acquired a new stake in shares of Hologic during the second quarter worth approximately $48,888,000. Old Mutual Global Investors UK Ltd. increased its stake in shares of Hologic by 276.7% in the second quarter. Old Mutual Global Investors UK Ltd. now owns 1,818,296 shares of the company’s stock worth $62,913,000 after buying an additional 1,335,551 shares in the last quarter. Finally, Highbridge Capital Management LLC acquired a new stake in shares of Hologic during the second quarter worth approximately $45,302,000. 94.51% of the stock is owned by institutional investors and hedge funds.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.